Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 11/20 | 0.66 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.53 |
| ▸ | FUT6 | P51993 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14178451 | 0.91 | KRAS (0.68) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL25893051 | 0.89 | KRAS (0.51) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL25892953 | 0.89 | FUT5 (0.67) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL25962086 | 0.89 | KRAS (0.64) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL25892793 | 0.89 | KRAS (0.64) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL25898890 | 0.88 | FUT5 (0.66) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL25962935 | 0.88 | FUT5 (0.73) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL25899459 | 0.88 | FUT5 (0.73) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL25891152 | 0.88 | FUT5 (0.73) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL29393705 | 0.86 | FUT5 (0.73) | KRASTGM2FUT5NT5EP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | KRAS 4257/4885TGM2 179/4885FUT5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.